



Further expanding one of the deepest pipeline in the sector with

## **DUAL ACTION LRRC15-TARGETING MONOCLONAL ANTIBODY FROM UCLA**

April 2022


***Riccardo Canevari***

*CEO, Radiopharm Theranostics Ltd*



# INVESTMENT HIGHLIGHTS

## In-licensing from UCLA **DUAL ACTION LRRC15-TARGETING MONOCLONAL ANTIBODY**



*LRRC15-targeting antibody "DUNP19" holds the potential of first in class therapy in different solid tumor types.*

### THE ROAD AHEAD

**mAb manufacturing**  
*Less than 6 months for cGMP*

**Phase 1 DUNP19**  
*12month to be started*

**Lead indication:  
Osteosarcoma (OS)**  
*high unmet need, orphan status,  
fast approval & limited  
competition*

# THE TECHNOLOGY & MoA

LRRC15 expression is produced by cancer cells  
AND the surrounding tumour micro-  
environment, but not by healthy normal tissues.

LRRC15 production is very high in aggressive and  
treatment-resistant tumours.

The LRRC15-targeted radiopharmaceutical  
therapy has unique “dual action,” i.e. targeting  
both the tumour cells and the surrounding  
environment (stroma).

The radionuclide carrying LRRC15-targeting  
antibody “DUNP19” holds the potential of first in  
class therapy in a range of solid tumour types.

Osteosarcoma has a high unmet medical need and impacts young adult population most commonly,  
which is the first disease against which this antibody will be tested.

# INVENTOR & INSTITUTION



## Dr. David Ulmert, MD, PhD

Dr Ulmert obtained his degrees from Lund University, Sweden. He is currently lab head, faculty member and director of the preclinical theranostics program at the department of molecular and medical, UCLA.

Prior to joining UCLA, Dr. Ulmert spent 9 years at MSKCC where he served as the technical director of Ludwig Center for Cancer Immunotherapy between 2014-2018. In addition, Dr. Ulmert holds a position as lab head at the department of oncology at Lund University, Sweden.

His research focus on development of multimodal vehicles targeting biomarkers related to progression and treatment resistance in oncological diseases. Several of the inventions developed by his teams are currently being evaluated in clinical trials.

Dr. Ulmert has co-founded biotech start-ups (Diaprost and Pharma15) that have successfully out-licensed several radiotheranostic and immunotherapeutic compounds. He serves as a scientific advisor to several pharmaceutical companies, including RAD.




- The **University of California, Los Angeles (UCLA)**
  - UCLA is frequently **ranked among the best universities in the United States** by major college and university rankings.
  - As of October 2021, 27 Nobel laureates, five Turing Award winners, two Chief Scientists of the U.S. Air Force and one Fields Medalist have been affiliated with UCLA as faculty, researchers or alumni.
  - Among the current faculty members, 55 have been elected to the National Academy of Sciences, 32 to the National Academy of Engineering, 41 to the National Academy of Medicine and 156 to the American Academy of Arts and Sciences.
  - The university was elected to the Association of American Universities in 1974.





# PRECLINICAL DATA – THE TARGET:

## Leucin Rich Repeat Containing Protein 15 (LRRC15)




# PRECLINICAL DATA – THE TARGET:

## LRRC15 has very limited expression in Healthy tissues



**FAP**



**LRRC15**



Note: Different scale on y-axis


1. Adrenocortical carcinoma
2. Bladder Urothelial Carcinoma
3. Breast invasive carcinoma
4. Cervical/endocervical carcinoma
5. Cholangio carcinoma
6. Colon adenocarcinoma
7. Lymphoid neoplasm/B-cell lymphoma
8. Esophageal carcinoma
9. Glioblastoma multiforme
10. Head and neck squamous cell carcinoma
11. Renal chromophobe
12. Renal clear cell carcinoma
13. Renal papillary cell carcinoma
14. Acute Myeloid Leukemia
15. Lower grade glioma
16. Hepatocellular carcinoma
17. Lung adenocarcinoma
18. Lung Squamous cell carcinoma
19. Ovarian serous cystadenocarcinoma
20. Pancreatic adenocarcinoma
21. Pheochromocytoma
22. Prostate adenocarcinoma
23. Rectum adenocarcinoma
24. Sarcoma
25. Cutaneous melanoma
26. Stomach adenocarcinoma
27. Testicular Germ cell tumors
28. Thyroid carcinoma
29. Thymoma
30. Endometrial carcinoma
31. Uterine carcinosarcoma



# PRECLINICAL DATA – THE MOLECULE:


## Humanized Monoclonal Antibody DUNP19

### Unique MoA and very fast internalization



# PRECLINICAL DATA:

## mAb DUNP19 in Osteosarcoma in vivo model






# PRECLINICAL DATA:

## mAb DUNP19 in Osteosarcoma in vivo model



### Osteosarcoma - single dose



# PRECLINICAL DATA:

## mAb DUNP19 in Osteosarcoma in vivo model


### Osteosarcoma - multiple doses



# PRECLINICAL DATA:


## mAb DUNP19 in Glioblastoma in vivo model

### U118 (GBM) s.c. tumors






# CLINICAL DEVELOPMENT PLAN: OVERVIEW



**Phase 1 in young ADULTS with metastatic OS**

# CLINICAL DEVELOPMENT PLAN:

High unmet need when LRRC15 is highly expressed



# Osteosarcoma (OS): LRRC15



- Primarily a disease of children and adolescents
  - 8<sup>th</sup> most common cancer in children
- Painful, disfiguring, and often rapidly fatal:
  - 8% originate in face
  - one of the very few cancers that metastasizes to the face

**Treatment is wide surgical excision of bone  
and highly toxic, intra-arterial chemotherapy cocktails**





## KEY STATISTICS FOR OSTEOSARCOMA



## THERAPEUTIC OPTIONS



## COMPETITION

Osteosarcoma is  
**linked to very poor prognosis**

Surgery

No targeted therapies approved  
in Osteosarcoma by FDA

Each year, about **1,000 new cases**  
are diagnosed in USA


Chemotherapy

No radiopharmaceutical  
therapies reported to be in  
clinical development yet

Most osteosarcomas occur in  
children, teens, and young adults  
**between the ages of 10 and 30.**

External Beam radiation

## mAb manufacturing



**INNOVAGEN AB**  
SE-22370 Lund  
Sweden

## IP



- First patent number 63/003,598 filed 18 Mar 2020
- Patent number P-594449-PC claims priority
- Worldwide coverage
- Expected loss of exclusivity March 2041

# SUMMARY

- High potential radiopharmaceutical therapy in-licensed by top institution (UCLA)
- Targeting LRCC15, expressed in multiple tumor types
- Unique DUAL ACTION against the tumor and its microenvironment
- Potential first in class in high unmet medical need disease (Osteosarcoma)
- No / very limited competition
- Good financial terms



## CONTACT US

---

### **Riccardo Canevari**

CEO & MANAGING DIRECTOR  
Radiopharm Theranostics Limited

T +1 862 309 0293

E [rc@radiopharmtheranostic.com](mailto:rc@radiopharmtheranostic.com)

W [www.radiopharmtheranostics.com](http://www.radiopharmtheranostics.com)

### **Paul Hopper**

Executive Chairman  
Radiopharm Theranostics Limited

T +61 406 671 515

E [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

W [www.radiopharmtheranostics.com](http://www.radiopharmtheranostics.com)